Cancer Survivorship
Up to 58% of cancer patients are at risk for developing limb lymphedema.1 Treatment can cause changes in weight, muscle mass, bone health , and nutrition, impacting quality of life.
Detect Early. Intervene Sooner. Achieve Better Outcomes.
ImpediMed’s SOZO® Digital Health Platform is the only FDA-Cleared Bioimpedance Spectroscopy (BIS) technology that non-invasively measures fluid status and tissue composition in healthy and unhealthy patient populations. BIS enables clinicians to precisely monitor key health indicators, helping them to optimize real-time, personalized care.
Discover SOZO
Addressing Significant Chronic Health Challenges
Wellness & Weight Management
Rapid weight reduction with GLP-1s or other therapies can affect muscle mass by up to 20%.2,3 IV therapies must be closely monitored for fluid sensitivities.
Heart Health Management
Heart failure (HF) affects ~64 million people world-wide.4 ~50% of patients with heart failure are overweight or obese.5
PLATFORM TECHNOLOGY
BIS Technology Enables Whole Body Insights for Personalized Care
By measuring 256 frequencies in a single, rapid scan, BIS separates intra- and extracellular fluid for an accurate whole-body composition profile. Powered by BIS, the SOZO® Digital Health Platform delivers actionable data at the point of care, enabling informed treatment, recovery, and clinical decision-making with confidence.
CONNECTED CARE SOLUTIONS
SOZO® Applications
L-Dex® Analysis
Detecting lymphedema early, at a subclinical stage, can help prevent progression to a chronic condition.
BodyComp™ Analysis
Tracking fluid volumes and tissue composition can inform clinical decisions and motivate patient compliance for improved outcomes.
HF-Dex® Analysis
Understanding dynamic changes in fluid volume can provide a more complete picture of disease progression and treatment success.
PERSONALIZED CARE
Real-Time Insights Delivered Across the Patient Care Continuum
From cancer survivorship, to heart health and wellness, the SOZO Digital Health Platform monitors patients for real-time changes to fluid status and tissue composition. With a cloud-connected platform, patients can be monitored and tracked across their treatment journey for comprehensive, personalized care.
References
- American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.
- Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024 Sep:26 Suppl 4:16-27. doi: 10.1111/dom.15728
- Mozzafarian et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition Volume 122, Issue 1, July 2025, Pages 344-36
- Bahira Shahim Global Public Health Burden of Heart Failure: An Updated Review; Card Fail Rev. 2023 Jul 27;9:e11. doi: 10.15420/cfr.2023.05
- Shen et al Understanding Obesity-Related High Output Heart Failure and Its Implication Int J Heart Fail. 2021 Jan 13;3(3):160–171. doi: 10.36628/ijhf.2020.0047